Genome-wide Analysis of the Alternative Splicing Profiles Revealed Novel Prognostic Index for Kidney Renal Cell Clear Cell Carcinoma

Li Gao¹#, Rong-quan He²#, Zhi-guang Huang¹, Yi-wu Dang¹, Yong-yao Gu¹, Hai-biao Yan³, Sheng-hua Li³*, Gang Chen¹*

1. Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China
2. Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China
3. Department of Urology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China

# Li Gao and Rong-quan He contributed equally to this study.
* Corresponding authors: Sheng-hua Li: Tel: +86 0771-5356533; Fax: 0086-771-5350031; Email: 13877115066@163.com; Gang Chen: Tel: +86 0771-5356534; Fax: 0086-771-5356534; Email: chengang@gxmu.edu.cn

Abstract

Alternative splicing (AS) is a major mechanism that greatly enhanced the diversity of proteome. Mounting evidence demonstrated that aberration of AS are important steps for the initiation and progression of human cancers. Here, we comprehensively investigated the association between whole landscape of AS profiles and the survival outcome of renal cell carcinoma (RCC) patients using RNA-seq data from TCGA SpliceSeq. Because of the limited number size of deaths in kidney chromophobe renal cell carcinoma (KICH) and papillary renal cell carcinoma (KIRP) TCGA cohorts, we only conducted survival analysis in kidney clear renal cell carcinoma (KIRC). We further constructed prognostic index (PI) based on prognosis-related AS events and built correlation network for splicing factors and prognosis-related AS events. According to the results, a total of 5351 AS events in 3522 genes were significantly correlated with the overall survival (OS) of kidney clear cell renal cell carcinoma (KIRC) patients. Seven of the PI models exhibited preferable prognosis-predicting capacity for KIRC with PI-ALL reaching the highest area under curve value of 0.875. The splicing regulatory network between splicing factors and prognosis-related AS events depicted a tangled web of relationships between them. One of the splicing factors: KHDRBS3 was validated by immunohistochemistry to be down-regulated in KIRC tissues. In conclusion, the powerful efficiency of risk stratification of PI models indicated the potential of AS signature as promising prognostic markers for KIRC and the splicing regulation network provided possible genetic mechanism of KIRC.

Key words: alternative splicing; prognostic index; splicing factor; kidney clear renal cell carcinoma; the cancer genome atlas.

Introduction

Renal cell carcinoma (RCC) is the most prevalent type of adult kidney cancer and is responsible for 14970 new deaths in 2018 worldwide [1, 2]. RCC can be histological divided into three major subtypes with different genetic drivers and clinical courses: clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (PRCC) (including type1 and type2) and chromophobe renal cell carcinoma (ChRCC) [3]. Although good effects have been achieved in the treatment of localized RCC using nephrectomy, advanced RCC remained incurable with poor survival outcome due to resistance to radiotherapy and
chemotherapy targeting tumor vasculature [4-7]. Therefore, it is crucial to find new prognostic predictors for the guidance of clinical therapy of RCC.

Alternative splicing (AS) is a pivotal process that increases the protein complexity through enabling the generation of multiple splice isoforms from an individual gene [8, 9], during which specific introns were selectively excised from the pre-mRNA and residual exons were rejoined [10]. A growing body of researches suggested that aberration of AS are important steps for the initiation and progression of human cancers [11-13]. In RCC, disturbance of AS of genes such as EZH2, PKM and FGFR2 have been observed by previous studies and isoform switches of these genes played active roles in the proliferation, growth and invasion of RCC [8, 14, 15], which demonstrated the immense value of AS in developing novel anti-cancer strategies for RCC. However, the prognostic significance of AS events was investigated for single or few genes in the past research and rarely has researchers worked out AS and splicing factor-based risk signature from the prognostic evaluation of whole AS or splicing factor profiles in RCC. The regulation mechanism of AS and splicing factor in KIRC has not been fully elucidated.

The feasibility of AS-based risk signature have been proved in non-small cell lung cancer, ovarian cancer, bladder cancer and gastrointestinal pan-adenocarcinomas [16-19], where AS-based risk signature have excellent distinguishing ability for the prognosis of low-risk and high-risk patients. Thus, we attempted to offer novel approach to prognostic stratification for RCC patients from the respective of AS and splicing factor. In this study, the most shining highlight of the work lies in that we for the first time conducted comprehensive assessment of the prognostic value of whole landscape of AS events in three major subtypes of RCC with available data from the cancer genome atlas (TCGA) and further constructed prediction models based on prognostic AS events and splicing factors for kidney renal clear cell carcinoma (KIRC). We also endeavored to comprehend the interaction mechanism between AS and splicing factor events on prognosis of KIRC patients through constructing regulation network of AS and splicing factors.

Results

**Prognosis-related AS Events from univariate Cox regression analysis**

According to the including criteria of eligible cases, a total of 62 KICH, 468 KIRC, 122 KIRP type 1 and 53 KIRP type 2 patients were enrolled in this study. The distribution of AS events in the above major subtypes of RCC was summarized in Figure 1A. For all major subtypes of RCC, exon skip (ES) was the predominant splicing type with the highest number of AS events. Because of the limited number size of deaths in KICH and KIRP TCGA cohorts, we only conducted survival analysis in KIRC. Detailed clinical information for the included 468 KIRC patients was summarized in Table 1. Results from univariate Cox regression analysis revealed thousands of prognosis-related AS events in KIRC, consisting of 290 alternate acceptor site (AAs) in 267 genes, 281 alternate donor site (ADs) in 255 genes, 1943 alternate promoter (AP)s in 1031 genes, 736 alternate terminator (AT)s in 402 genes, 1490 ESs in 1082 genes, 30 mutually exclusive exons (MEs) in 30 genes and 581 retained intron (RIs) in 455 genes (Figure 1B). As the upset plot illustrated, a single gene might have up to four prognosis-related AS events (Figure 2).

**Table 1. Clinical characteristics of the 468 KIRC patients.**

| Variables | Patient characteristics |
|-----------|-------------------------|
| Age, mean years ± SD | 60.18±12.05 |
| Overall survival time, mean days ± SD | 1180.71±763.54 |
| Sex, n (%) | Male 309, Female 159 |
| Prior malignancy, n (%) | Yes 68, No 400 |
| Synchronous malignancy, n (%) | Yes 3, No 398 |
| Race, n (%) | Asian 8, Black or African American 36, White 418 |
| Ethnicity, n (%) | Hispanic or Latino 25, Not Hispanic or Latino 300 |
| Tumor stage, n (%) | Stage I 232, Stage II 50, Stage III 106, Stage IV 77 |
| Overall status, n (%) | Alive 325, Dead 143 |

**Protein-to-protein interaction (PPI) network and pathway annotation for genes of prognosis-related AS events**

The PPI network in Figure 3 displayed the interactions between genes of top 1000 prognosis-related AS events in KIRC. Calculation of connection degrees returned the following list of hub genes: HERC2, UBE3A, UBA1, SIAH1 and RPS9.

Enrichment of genes of top 1000 prognosis-related AS events in KIRC was recorded detailedy in Table 2. Top three significant pathways
assembled by these genes were herpes simplex infection, ribosome and autophagy - other (Figure 4).

**Construction of PI models**

Data of AS events from multivariate Cox regression analysis that were adopted as components

---

**Figure 1.** The distribution of all AS events and prognosis-related AS events in KIRC. A: Blue bars and orange bars indicated the number of AS events and the corresponding genes in each splicing type, respectively. B: The distribution of prognosis-related AS events in KIRC. Blue bars and orange bars indicated the number of prognosis-related AS events and the corresponding genes in each splicing type, respectively. AA: alternate acceptor site; AD: alternate donor site; AP: alternate promoter; AT: alternate terminator; ES: exon skip; ME: mutually exclusive exons; RI: retained intron.

**Figure 2.** UpSet plot of survival-associated AS events. The UpSet plot illustrates the interactions among seven types of survival-associated alternative splicing (AS) events in KIRC. A single gene could have up to four types of prognosis-related AS events.
of PI models were listed in Table 3. Overall, Kaplan-Meier analysis demonstrated the satisfactory risk-stratification ability of PI models in KIRC with the exception of PI-AP (P<0.001) (Figure 5). Time-dependent receiver operator characteristic (tROC) curves further confirmed the predicting efficiency of PI models in KIRC. Emerging as the PI models with strongest predicting efficiency from the moderate property in general level of all PIs, the area under curves (AUC) values of three PIs reached over 0.8 (PI-AA, PI-ME and PI-ALL) and AUC value of PI-ALL was the highest of all (AUC=0.875) (Figure 6).

Figure 3. PPI network for genes of top 1000 prognosis-related AS events. The PPI network, comprised of 220 nodes and 466 links, described the interactions between genes corresponding to top 1000 prognosis-related AS events. Nodes with different colors represented different proteins and the edges between nodes represented known interactions or predicted interactions between these proteins.

Table 2. KEGG annotation for genes of top 1000 prognosis-related AS events in KIRC

| ID    | Description                              | GeneRatio | Bg Ratio | P value     | Q value     | Count |
|-------|------------------------------------------|-----------|----------|-------------|-------------|-------|
| hsa05168 | Herpes simplex infection                 | 15/259    | 185/7470 | 0.001859621 | 0.31156072  | 15    |
| hsa03010 | Ribosome                                 | 13/259    | 153/7470 | 0.00245708  | 0.31156072  | 13    |
| hsa04136 | Autophagy - other                        | 5/259     | 32/7470  | 0.004505404 | 0.31156072  | 5     |
| hsa03410 | Base excision repair                     | 5/259     | 33/7470  | 0.005162598 | 0.31156072  | 5     |
| hsa04623 | Cytosolic DNA-sensing pathway             | 7/259     | 63/7470  | 0.005856499 | 0.31156072  | 7     |
| hsa03450 | Non-homologous end-joining               | 3/259     | 13/7470  | 0.009102644 | 0.40355611  | 3     |
| hsa04621 | NOD-like receptor signaling pathway       | 12/259    | 168/7470 | 0.013668241 | 0.319399161 | 12    |
| hsa02010 | ABC transporters                         | 5/259     | 44/7470  | 0.017363984 | 0.577352452 | 5     |
| hsa04146 | Peroxisome                               | 7/259     | 83/7470  | 0.024570315 | 0.705407061 | 7     |
| hsa04620 | Toll-like receptor signaling pathway      | 8/259     | 104/7470 | 0.027553359 | 0.705407061 | 8     |
| hsa05132 | Salmonella infection                      | 7/259     | 86/7470  | 0.029170969 | 0.705407061 | 7     |
| hsa04380 | Osteoclast differentiation                | 9/259     | 128/7470 | 0.033416332 | 0.740728694 | 9     |
Table 3. Multivariate Cox regression analysis of prognosis-related events for KIRC

| PI model | Splicing Gene symbol | AS ID | Exons | From exon (%) | To exon (%) | Hazard ratio | P-value |
|----------|----------------------|-------|-------|---------------|-------------|--------------|---------|
| PI-AT    | AA                   | TAF1D | 1     | 7             | 83          | 1.046        | 0.005   |
|          | AA                   | GIT2  | 1     | 7             | 83          | 1.06         | 0.005   |
|          | AA                   | CEP76 | 1     | 7             | 83          | 1.06         | 0.005   |
|          | AA                   | WBS4C27 | 1     | 7             | 83          | 1.06         | 0.005   |
|          | AD                   | TTC14 | 1     | 7             | 83          | 1.06         | 0.005   |
|          | AD                   | TG16D | 1     | 7             | 83          | 1.06         | 0.005   |
|          | AD                   | SLCS2A3 | 2     | 7             | 83          | 1.06         | 0.005   |
|          | AD                   | TMEM35D | 2     | 7             | 83          | 1.06         | 0.005   |
|          | AP                   | UCA   | 1     | 7             | 83          | 1.06         | 0.005   |
|          | AP                   | GRPS6 | 2     | 7             | 83          | 1.06         | 0.005   |
|          | AP                   | KIAA1090 | 3     | 7             | 83          | 1.06         | 0.005   |
|          | AP                   | HHILX | 2     | 7             | 83          | 1.06         | 0.005   |
|          | AT                   | ZNF814 | 9     | 7             | 83          | 1.06         | 0.005   |
|          | AT                   | AGL15 | 16    | 7             | 83          | 1.06         | 0.005   |
|          | AT                   | EPB4I | 17    | 7             | 83          | 1.06         | 0.005   |
|          | AT                   | FARP2 | 18    | 7             | 83          | 1.06         | 0.005   |
|          | AT                   | PKCS5 | 38    | 7             | 83          | 1.06         | 0.005   |
|          | ES                   | FAM210A | 25    | 7             | 83          | 1.06         | 0.005   |
|          | ES                   | GK    | 23    | 7             | 83          | 1.06         | 0.005   |
|          | ES                   | RPL13A | 22    | 7             | 83          | 1.06         | 0.005   |
|          | ME                   | STHA3 | 21    | 7             | 83          | 1.06         | 0.005   |
|          | ME                   | ZFPI  | 17    | 7             | 83          | 1.06         | 0.005   |
|          | ME                   | TMEM67 | 45    | 7             | 83          | 1.06         | 0.005   |
|          | ME                   | ZNF45 | 38    | 7             | 83          | 1.06         | 0.005   |
|          | PI                   | FBXO3 | 12    | 7             | 83          | 1.06         | 0.005   |
|          | PI                   | MTERFD3 | 12   | 7             | 83          | 1.06         | 0.005   |
|          | PI-AL    | AAPC | 12    | 7             | 83          | 1.06         | 0.005   |
|          | PI-AL    | WDR6  | 41    | 7             | 83          | 1.06         | 0.005   |
|          | PI-AT    | FAM120C | 2    | 7             | 83          | 1.06         | 0.005   |
|          | PI-AT    | GK    | 23    | 7             | 83          | 1.06         | 0.005   |

Note: AA: alternate acceptor; AD: alternate donor; AP: alternate promoter; AT: alternate terminator; ME: mutually exclusive exons; PI: retained intron.

Table 4. Prognosis-related splicing factors from univariate Cox regression analysis

| Splicing factor | HR (95% CI) | Lower CI | Higher CI | P-value |
|----------------|-------------|----------|-----------|---------|
| PCK1          | 0.99625078  | 0.99804927 | 0.99804927 | 8.67E-08 |
| hnrNPK        | 0.996168459 | 0.99457085 | 0.9977686 | 2.7E-06 |
| KHDRBS1       | 0.99273841  | 0.99497039 | 0.99471921 | 1.4E-05 |
| hnrNPA1       | 0.997840809 | 0.99652893 | 0.99855271 | 3.1E-05 |
| RBM6          | 0.998084368 | 0.99835785 | 0.99849081 | 8.79E-03 |
| KHDRBS3       | 0.88499718  | 0.83122615 | 0.84030595 | 8.94E-05 |
| hnrNPNU       | 0.99282926  | 0.98914486 | 0.9949427 | 0.000013124 |
| hnrNPM        | 0.98975287  | 0.98430709 | 0.9952886 | 0.000025332 |
| NOVA2         | 0.9000193   | 0.86272317 | 0.95776319 | 0.000243576 |
| HTRA2         | 0.96538335  | 0.94405899 | 0.98403167 | 0.000429006 |
| S1F1          | 0.99181702  | 0.98712205 | 0.99639353 | 0.00396623 |
| hnrNPF        | 0.99473243  | 0.99161076 | 0.99780662 | 0.00078522 |

HR: hazard ratio

Table 5. KHDRBS3 expression in KIRC and paracarcinoma tissues

| Tissue type | KHDRBS3 expression | P-value |
|-------------|--------------------|--------|
| KIRC (n=10) | negative, n (%)   | 0 (0)  |
|             | positive, n (%)    | 10 (100) |
| Paracarcinoma (n=10) | negative, n (%)   | 0 (0)  |
|             | positive, n (%)    | 10 (100) |

Note: KIRC: kidney renal clear cell carcinoma.

To test the ability of PI models with the strongest predicting efficiency in prognosticating the survival condition of patients in different group of clinical advances, Kaplan-Meier survival analysis was performed to appraise the prognostis-predicting capacity of PI-ALL in stage I-II and stage III-IV groups of KIRC patients, respectively (Figure 7). Expectedly, PI-ALL showed excellent performance in separating overall survival (OS) conditions of low and high risk RCC patients both in stage I-II and stage III-IV patient groups.

Regulation network involving splicing factors and prognosis-related AS events

We obtained information of 66 splicing factors from SpliceAid2 and univariate Cox regression analysis for all the 66 splicing factors indicated 12 prognosis-related splicing factors in KIRC (Table 4). Interestingly, most of the prognosis-related splicing factors in KIRC heralded relatively good survival outcome of KIRC patients (hazard ratio (HR)<1). A total of 12 splicing factors showed obviously high correlation with the survival condition of KIRC patients (Figure 8 and 9A). From the 12 significant prognosis-related splicing factors, three splicing factors including PCBPI, KHDRBS3 and HTRA2 were selected from multivariate Cox regression analysis for the construction of splicing factor-based PI and this PI demonstrated moderate prognostic stratification ability (AUC=0.743, P<0.001) (Figure 9B and C). We selected the 12 significant prognosis-related splicing factors (P<0.001) in KIRC to conduct Pearson’s correlation analysis of the association between these splicing factors and top ten prognosis-related AS events in KIRC. The correlation network in Figure 10 revealed the positive (red lines) or negative (blue lines) regulatory relationships between splicing factors (blue dots) and AS events (red dots).

Immunohistochemistry (IHC) of KHDRBS3

Immunostaining images of KHDRBS3 in ten pairs of KIRC and paracarcinoma tissues were displayed in Figure 11. KHDRBS3 was primarily expressed in cytoplasm. The positive expression of KHDRBS3 was observed in 0 (0%) and 10 (100%) cases of KIRC and adjacent normal tissues, respectively (Table 5, P<0.0001), which proved that KHDRBS3 was down-regulated in KIRC compared with para-carcinoma tissues.

Discussion

Currently AS has been proposed as the addition to the growing list of cancer hallmarks [20]. Impressed by the profound influences exerted by dysregulated AS events in human cancers, we are propelled to explore the prognostic significance of AS events and the underlying mechanism in RCC. Despite Song J et al. has built a preliminary prognostic model for KIRC based on profiles of AS events; they simply constructed the prognostic model and there was no
validation of results or deep exploration of mechanism [21]. Moreover, the study of Song J et al. ignored the prognostic role of splicing factors in KIRC and the regulatory relationship between AS and splicing factors in KIRC. Compared to the work of Song J et al., we constructed prediction models based on both prognostic AS events and splicing factors for kidney renal clear cell carcinoma (KIRC). We also constructed regulation network of AS and splicing factors to comprehend the interaction mechanism between AS and splicing factor events on prognosis of KIRC patients. One of the prognostic splicing factor (KHDRBS3) was validated by IHC to be downregulated in KIRC.

Figure 4. Circle map and dot plot of KEGG enrichment for genes of top 1000 prognosis-related AS events. (A): Circle map. Ribbons with different colors in the right half circle represented top 12 significant KEGG pathways. The 12 top pathways were enriched by genes listed in the left half circle. (B): Dot plot. The color spectrum ranging from green to red indicated an increasing P value and the size of dot represented the number of genes assembled in specific pathway. Each dot in the plot represented specific pathway terms listed in y axis.
Figure 5. Kaplan-Meier survival analyses for eight prognostic indexes (Pis) in KIRC. Patients in different risk groups of KIRC was divided based on the median value of PSI value of AS events in PI-AA (A), PI-AD (B), PI-AP (C), PI-AT (D), PI-ES (E), PI-ME (F), PI-RI (G) and PI-ALL (H). Numbers of patients in low or high risk groups and censoring data at different time were displayed beneath the Kaplan-Meier survival curves.

Figure 6. Time-dependent ROC curves for assessing the predicting efficiency of eight PIs in KIRC. A: PI-AA; B: PI-AD; C: PI-AP; D: PI-AT; E: PI-ES; F: PI-ME; G: PI-RI; H: PI-ALL.
Figure 7. Evaluation of the prognostic value of PI-ALL in early or advanced clinical stage of KIRC patients from Kaplan-Meier survival analysis. A: Differential survival outcome between KIRC patients (stage I-II) in low and high risk groups. B: Differential survival outcome between KIRC patients (stage III-IV) in low and high risk groups.

Figure 8. Survival curves of significant prognosis-related splicing factors for KIRC. A: PCBP1; B: hnRNPK; C: KHDRBS1; D: hnRNPA0; E: RBMX; F: KHDRBS3; G: hnRNPU; H: hnRNPm; I: NOVA2; J: HTRA2; K: SF1; L: hnRNPF. Median expression value was set as cutoff value. The survival curves reflected the increase in the percentage of deaths over time.
Transcriptome-wide analysis of the AS profiling landscape revealed thousands of prognosis-related AS events in KIRC. It is noteworthy that 15 of all the prognosis-related genes possessed four splicing types, involving several genes with critical functions in KIRC such as PLAGL1 and NDRG2. PLAGL1 was originally reported to act as tumor suppressor in several types of human tumors via cell-cycle arresting and pro-apoptotic effect [22, 23]. Recently the oncogenic role of PLAL1 in KIRC was discovered that PLAGL1 upregulation in KIRC tissues was positively associated with distant metastasis and poor survival [23]. Indeed most of the prognosis-related splicing isoforms of PLAGL1 in the present study indicated worse clinical outcome (HR>1). NDRG2, one of the members of the N-Myc downstream-regulated gene family, was shown by Ma JJ, et al. and Shi W et al. to demonstrate anti-tumor activity in KIRC through inhibiting KIRC cell proliferation and restraining the glycolysis and glutaminolysis process in KIRC [24, 25]. Albeit the reported tumor suppressive role of NDRG2 in KIRC, the vast majority of splice variants stemmed from NDRG2 were negatively associated with the OS of KIRC. We conjectured that this phenomena should be attributed to the fact that properties of proteins encoded by different splice isoforms varies from even opposite to each other [20].

To gain deeper insights into the mechanism of prognosis-related AS events in KIRC, we performed KEGG pathway analysis and PPI network for genes corresponding to top 1000 prognosis-related AS events. KEGG pathway annotation revealed key clues for the function of prognosis-related AS events in KIRC that herpes simplex infection, ribosome and autophagy - other were three most significant pathways enriched by prognosis-related AS event in KIRC. Of the thee terms, autophagy, an evolutionary conserved process that refers to the sequestration and delivery of organelles and macro-molecules to lysosome for degradation [26], was closely correlated with human cancers with implications in multiple properties of cancer including motility, invasion, metastasis, epithelial-mesenchymal transition, drug resistance, and immune evasion of tumor cells [27]. It is conceivable that the disturbance of above-mentioned pathways caused by AS events were of importance in the pathogenesis of KIRC.
Figure 10. Splicing regulation network in KIRC. Blue and red notes in the network represented prognosis-related splicing factors and AS events, respectively. The gradually changing colors from blue to red indicated transition of correlations between splicing factors and AS events from negative to positive.

Figure 11. Representative images of immunostaining for KHDRB3 in KIRC and adjacent normal tissues. A: Immunostaining of KIRC tissues (x100); B: Immunostaining of KIRC tissues (x200); C: Immunostaining of KIRC tissues (x400); D: Immunostaining of normal tissues (x100); E: Immunostaining of normal tissues (x200); F: Immunostaining of normal tissues (x400). The brown area in Figure 11D-F marked the positive staining of KHDRB3 in adjacent normal tissues.
Based on the prognosis-related AS events, we constructed eight prediction models grouped by splicing types. Further evaluation from Kaplan-Meier survival analysis and tROC curves reflected the preferable prognosis-predicting ability of seven PI models (PI-AA, PI-AD, PI-AT, PI-ES, PI-ME, PI-RI and PI-ALL). Although some prediction models composed of miRNAs or mRNAs have been devised by other researchers [28, 29], we are confident of the strong risk-stratification capacity of our PIs. The highest AUC value from the seven PI models was close to 0.9, obviously higher than that of the five-gene signature in the study of Zhan Y et al. [29]. Unlike the study of Liang B et al., where the three miRNA constituents for prediction models came from the overlapping parts of OS markers, disease-free survival markers and diagnostic markers [28], AS events included for PI in the present study were selected from two steps: univariate Cox regression analysis and multivariate Cox regression analysis. Methodological differences between our study and the study of Liang B et al. may lead to different AUC values of prediction models. On balance, PIs proposed in our study embodies the novelty of our work in that we are the first group to construct PI models for KIRC from the perspective of AS and PI models in the current work performed well in predicting the survival of KIRC patients.

It is widely acknowledged that splicing factors were key regulators of AS [30]. Hence, we further concentrated on prognosis-related splicing factors and their correlation with top 10 prognosis-related AS events in each splicing type. A total of 12 splicing factors were significantly associated with the OS of KIRC, among which splicing factors such as PCBP1, hnRNPK and hnRNPM were engaged in tumorigenesis through guiding alternative splicing programs in various cancers [31-33]. One of the splicing factors: KHDRBS3 showed significant decreased expression in KIRC tissues from IHC experiment. Down-regulation of KHDRBS3 was consistent with the indication of good prognosis (HR<1), which indirectly validated the prognostic value of KHDRBS3 in KIRC. The correlation network between splicing factors and prognosis-related AS events depicted the complicated relationships between them. Multiple splicing factors coordinated to mediate prognosis-related AS events, thus affecting the survival of KIRC patients. The creation of correlation network marked a step forward for us in deciphering the regulatory mechanism of AS events in KIRC.

Despite the encouraging findings in the present study, room for improvements remains for this study. The original intention was to conduct survival analysis of AS events in pan-kidney cancers. However, the small number of deaths restrained us from performing survival analysis for AS events in other subtypes of RCC: KICH, KIRP type 1 and KIRP type 2. There is a lack of testing set of for the verifying the prognosis-predicting ability of PIs in KIRC after the construction of PIs. Moreover, the biological function of AS events in KIRC and the relationships between splicing factors and AS events needed experimental validation. All of these defects pointed out directed the future efforts of our work.

In summary, PIs based on prognosis-related AS events were constructed by univariate and multivariate Cox regression analysis of AS profiles in KIRC. Subsequent evaluation results proved that risk-stratification by PI enabled the satisfactory differentiation of survival outcomes in KIRC patients. Additionally, the correlation network between splicing factors and prognosis-related AS events shed lights on the genetic mechanism of KIRC.

Methods

Curation and preprocess of TCGA data

AS profiles of RCC patients were generated using SpliceSeq, a java program that provides a clear view of the splicing patterns through accurate alignment of reads and exon-inclusion or skipping splice junction [34]. PSI values were calculated by SpliceSeq to quantify seven types of AS events [35]: ES, RI, ME, AD, AA, AP, and AT for three major types of RCC (KICH, KIRC and KIRP). We only included AS events that met the criteria of PSI value >75% and standard deviation >0.1 for this study. Clinical-pathological information of RCC was also downloaded from TCGA data portal.

Survival analysis

Three major types of RCC cases (KICH, KIRC and KIRP) with OS time over 90 days and PSI information of AS events were eligible for the present study; RCC cases were excluded from survival analysis if the criteria listed above was not met. We performed univariate Cox regression analysis R software v.3.5.1 to judge whether the AS events were prognosis-related or not according to the median of PSI value. Then, top ten prognosis-related AS events in each splicing type from KICH, KIRP type1 and KIRP type2 as well as top 50 prognosis-related AS events in each splicing type from KIRC were subjected to multivariate Cox regression analysis in SPSS v.22.0 for the identification of AS events appropriate for the construction of prediction models. Significant prognosis-related AS events from multivariate Cox regression analysis were included as components of PI models corresponding to each subtypes of RCC.
splicing type. Specifically, PI-ALL was built based on multivariate Cox regression analysis results of top ten or 50 prognosis-related AS events from all splicing types. The following formula was applied in calculation of PIs: \( PI = \sum_{i}^{n} PSI_i \times \beta_i \) (\( \beta \) is the regression coefficient). The predicting efficiency of each PI model was compared at 3000 days for fewer events occurred after 3000 days. Two-tailed P value of less than 0.05 was considered statistically significant. The interactive sets in seven splicing types of AS events were visualized and aggregated by UpSet package of R software v.3.5.1, which exhibited better performance than Venn plot when the number of datasets was more than five [36].

**Interaction network and pathway annotation for genes of prognosis-related AS events**

We uploaded genes of top 1000 prognosis-related AS events in all splicing types from univariate Cox regression analysis to online program: STRING v.10.5.0 for the creation of PPI network. The highest confidence (0.9) was assigned to the PPI network in order to guarantee the credibility of results. Genes in the PPI network with the highest connection degrees were defined as hub genes. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis for genes submitted to STRING was carried out by ClusterProfiler package of R software v.3.5.1. Terms with p value <0.05 were significant pathways enriched by these genes.

**Regulation network involving splicing factors and prognosis-related AS events**

Aware of the predominant position of splicing factors in mediating AS, we further investigated the regulatory relationships between splicing factors and AS events for three major types of RCC (KICH, KIRC and KIRP). Firstly, we downloaded information of humankind splicing factors from SpliceAid 2 (www.introni.it/spliceaid.html) [37]. Then transcripts per million (TPM) expression values of splicing factors in three major subtypes of RCC were deduced from read count values in TCGA data portal. Subsequent univariate Cox regression analysis was conducted to assess the prognostic value of splicing factors in each major subtype of RCC. Prognosis-related splicing factor were singled out for Pearson’s correlation analysis of the association between splicing factors and top ten prognosis-related AS events in each splicing type. Correlation diagrams representing the regulation between splicing factors and prognosis-related AS events for each major subtype of RCC were drawn by Cytoscape v.7.0.

**IHC of KHDRBS3**

Ten pairs of KIRC and adjacent normal tissues were collected from the First Affiliated Hospital of Guangxi Medical University during the period of September 2017 to February 2019. The experiments were approved by the Ethical Committee of the First Affiliated Hospital of Guangxi Medical University and written informed consent was signed by each participant. The standard procedures of IHC were described in detailed previously [38]. All samples were incubated using rabbit polyclonal anti-KHDRBS3 antibody (1:1000 dilution; catalog no. ab 881155445) overnight at 4°C. Two pathologists unaware of the clinicopathological data assessed the immunostained slides independently. The criteria for evaluation of IHC has been elaborated in previous study [38]. Analysis of KHDRBS3 expression patterns in KIRC and paracarcinoma tissues was performed via Wilcoxon signed-rank tests in SPSS v.22.0.

**Abbreviations**

RCC: renal cell carcinoma; AS: alternative splicing; KICH: kidney chromophobe renal cell carcinoma; KIRP: kidney papillary renal cell carcinoma; KIRC: kidney clear renal cell carcinoma; TCGA: the cancer genome atlas; AA: alternate acceptor site; AD: alternate donor site; AP: alternate promoter; AT: alternate terminator; ES: exon skip; ME: mutually exclusive exons; RI: retained intron; PSI: percent spliced in; OS: overall survival; PI: prognostic index; tROC: time-dependent receiver operating curves; AUC: area under curves; HR: hazard ratio; PPI: protein-to-protein; KEGG: kyoto encyclopedia of genes and genomes (KEGG).

**Acknowledgements**

The authors would like to thank the TCGA Spliceseq, TCGA database and SpliceAid 2 database for the availability of the data.

**Funding sources**

This study was funded by Guangxi Medical University Training Program for Distinguished Young Scholars, Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region Health and Family Planning Commission Self-financed Scientific Research Project (Z20180979), Guangxi Zhuang Autonomous Region University.
Student Innovative Plan (20180888), Fund of Natural Science Foundation of Guangxi, China (2018GXNSFAA281175) Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Chen YC, Huang BM, Lee WC, et al. 16-Hydroxyclerodadien-3,13-dien-15,16-olide induces anoikis in human renal cell carcinoma cells: involvement of focal adhesion disassembly and signaling. Onco Targets Ther. 2018; 11:7679-7690.
2. Lee SH, Lee WK, Kim N, et al. Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition. Cancers (Basel). 2018; 10:E455.
3. Ricketts CJ, De Cubas AA, Fan H, et al. The Cancer Genome Atlas Analyzes Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018; 25:3698.
4. Fernandez-Pello S, Hofmann F, Tahbaz R, et al. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. Eur Urol. 2017; 71:421-436.
5. Gu W, Zhu Y, Wang H, et al. Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case series. PLoS One. 2015; 10:e0118022.
6. Kini BI. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res. 2010; 16:1348-1354.
7. Sheng X, Chi Z, Cui C, et al. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget. 2016; 7:27044-27054.
8. Chen K, Xiao H, Zeng J, et al. Alternative Splicing of EZH2 pre-mRNA by SF3B1 Contributes to the Tumorigenic Potential of Renal Cancer. Clin Cancer Res. 2017; 23:3428-3441.
9. Li J, Wang Y, Rao X, et al. Roles of alternative splicing in modulating transcriptional regulation. BMC Syst Biol. 2017; 11(Suppl 5):S89.
10. Lehmann KV, Kahles A, Kandoth C, et al. Integrative genome-wide analysis of the determinants of RNA splicing in kidney renal clear cell carcinoma. Pac Symp Biocomput. 2015;44-55.
11. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unginged. Genes Dev. 2010; 24:2343-2364.
12. Oltean S, Bates DO. Hallmarks of alternative splicing in cancer. Oncogene. 2014; 33:5311-5318.
13. Singh RK, Cooper TA. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med. 2012; 18:472-482.
14. Jiang J, Chen X, Liu H, et al. Polypyrimidine Tract-Binding Protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM. Am J Cancer Res. 2017; 7:245-259.
15. Zhao Q, Caballero OL, Davis ID, et al. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res. 2013; 19:2460-2472.
16. He RQ, Zhou XG, Yi QY, et al. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on SpliceSeq Data from 317 Cases. Cell Physiol Biochem. 2018; 48:1355-1366.
17. Li Y, Sun N, Lu Z, et al. Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett. 2017; 393:40-51.
18. Lin P, He RQ, Ma FC, et al. Systematic Analysis of Survival-Associated Alternative Splicing Signatures in Gastrointestinal Pan-Adenocarcinomas. EBioMedicine. 2018; 34:46-60.
19. Zhu J, Chen Z, Yong L. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer. Gynecol Oncol. 2018; 145:368-374.
20. Ladomery M. Aberrant alternative splicing is another hallmark of cancer. Int J Cell Biol. 2013; 2013:463786.
21. Song J, Liu YD, Su J, et al. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma. J Cell Physiol. 2019; 234:22753-22764.
22. Huang SM, Schonthal AH, Stallcup MR. Enhancement of p33-dependent gene activation by the transcriptional coactivator Zac1. Oncogene. 2001; 20:2134-2143.
23. Godlewski J, Krazinski BE, Kowalczyk AE, et al. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis. Anticancer Res. 2016; 36:617-624.